Other substances

Povidone Iodine

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Marketed as

gel forming nasal spray IVIEW-1503 and ophthalmic eye drop IVIEW-1201

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations Preprint	VERO E6 cell cultures		IVIEW-1503 and IVIEW-1201 could be potential agents to reduce or prevent the transmission of the virus through the nasal cavity and the eye, respectively	May/20/2020
In Vitro Efficacy of Povidone-Iodine Nasal And Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) Preprint	VERO cells			May/26/2020

AI-suggested references

Link	Publication date
Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2).	Mar/13/2022
Virucidal Effect of Povidone Iodine on SARS-CoV-2 in Nasopharynx: An Open-label Randomized Clinical Trial.	May/06/2022
Changes in reverse transcription polymerase chain reaction cycle threshold values of SARS-CoV-2 with topical povidone iodine use: A single-arm open-label interventional study	Jan/18/2021
Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial.	May/18/2021
Combined Nasal, Oropharyngeal Povidone Iodine Plus Glycyrrhizic Acid Sprays, Accelerate Clinical and Laboratory Recovery and Reduces Household Transmission of SARS-CoV-2: A Randomized Placebo-Controlled Clinical Trial	May/18/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04941131	The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients	Not yet recruiting	Phase 4	Jul/01/2021	Mar/01/2022
Alternative id - 1485 Interventions - Drug: Chlorhexidine digluconate, povidone iodine Study type - Interventional Study results - No Results Available Locations - King Abdulaziz University , Faculty of Dentistry, Jeddah, Saudi Arabia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Treatment Enrollment - 60 Age - 21 Years to 80 Years (Adult, Older Adult) Outcome measures - quantity of the virus in the saliva measured by Q- PCR
NCT04603794	Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19	Recruiting	Phase 4	Oct/01/2020	Nov/01/2020
Alternative id - 2020H0346 Interventions - Drug: 0.5% Povidone Iodine\|Drug: 0.12% Chlorhexidine Gluconate Mouth Rinse\|Drug: 1% Hydrogen Peroxide\|Drug: 0.9% Normal Saline Study type - Interventional Study results - No Results Available Locations - The Ohio State University Wexner Medical Center, Columbus, Ohio, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Prevention Enrollment - 60 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - real time reverse transcriptase quantitative PCR\|ct values
NCT04371965	Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19	Completed	Phase 2	Sep/01/2020	Oct/23/2020
Alternative id - KILLER Interventions - Drug: Povidone-Iodine Study type - Interventional Study results - No Results Available Locations - University Hospital of Poitiers, Poitiers, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 24 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7\|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage\|Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal cell cultures\|Thyroid tests at Day0 and Day7\|Patient satisfaction at Day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort)\|Daily presence of clinical signs in favour of COVID-19, including respiratory distress using NYHA scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea\|Need for ward or intensive care hospitalization
NCT04549376	Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo	Completed	Phase 2	Jul/01/2020	Oct/30/2020
Alternative id - BRiCM-1131-2020 Interventions - Drug: Povidone-Iodine 0.4% NI\|Drug: Povidone-Iodine 0.5% NI\|Drug: Povidone-Iodine 0.6% NI\|Drug: Povidone-Iodine 0.5% NS\|Drug: Povidone-Iodine 0.6% NS\|Other: Placebo comparator: DW-NI\|Other: Placebo comparator: DW-NS Study type - Interventional Study results - No Results Available Locations - Dhaka Medical College, Dhaka, Bangladesh Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 200 Age - 15 Years to 90 Years (Child, Adult, Older Adult) Outcome measures - Proportion of COVID-19 positive cases following intervention\|Adverse events
NCT04721457	The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load	Completed	Phase 4	Jan/03/2021	Dec/10/2021
Alternative id - 1384 Interventions - Drug: Distilled Water\|Drug: 1% Povidone Iodine (PVP-I)\|Drug: 1.5% Hydrogen Peroxide (H2O2)\|Drug: 0.075% Cetylpyridinium Chloride (CPC)\|Drug: 0.1% Sodium Hypochlorite Study type - Interventional Study results - No Results Available Locations - Alhamra TETAMMAN clinic (PHC), Jeddah, Saudi Arabia Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 120 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in SARS-Cov-2 viral load (Quantitative Real-Time Reverse-Transcriptase Polymerase Chain Reaction (qRT-PCR))\|ct values

Export (.csv)